- Home
- CRESY vs SVRA Comparison
CRESY vs SVRA Comparison
Compare CRESY & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRESY
- SVRA
- Stock Information
- Founded
- CRESY 1936
- SVRA 2007
- Country
- CRESY Argentina
- SVRA United States
- Employees
- CRESY N/A
- SVRA N/A
- Industry
- CRESY Real Estate
- SVRA Biotechnology: Pharmaceutical Preparations
- Sector
- CRESY Finance
- SVRA Health Care
- Exchange
- CRESY Nasdaq
- SVRA Nasdaq
- Market Cap
- CRESY 615.0M
- SVRA 527.2M
- IPO Year
- CRESY 1997
- SVRA N/A
- Fundamental
- Price
- CRESY $9.14
- SVRA $3.60
- Analyst Decision
- CRESY
- SVRA Buy
- Analyst Count
- CRESY 0
- SVRA 8
- Target Price
- CRESY N/A
- SVRA $6.63
- AVG Volume (30 Days)
- CRESY 343.5K
- SVRA 1.7M
- Earning Date
- CRESY 11-07-2025
- SVRA 11-11-2025
- Dividend Yield
- CRESY 6.44%
- SVRA N/A
- EPS Growth
- CRESY N/A
- SVRA N/A
- EPS
- CRESY 0.12
- SVRA N/A
- Revenue
- CRESY $767,102,963.00
- SVRA N/A
- Revenue This Year
- CRESY N/A
- SVRA N/A
- Revenue Next Year
- CRESY N/A
- SVRA N/A
- P/E Ratio
- CRESY $6.69
- SVRA N/A
- Revenue Growth
- CRESY N/A
- SVRA N/A
- 52 Week Low
- CRESY $8.39
- SVRA $1.89
- 52 Week High
- CRESY $14.23
- SVRA $4.70
- Technical
- Relative Strength Index (RSI)
- CRESY 40.12
- SVRA 64.24
- Support Level
- CRESY $8.41
- SVRA $3.47
- Resistance Level
- CRESY $9.15
- SVRA $3.72
- Average True Range (ATR)
- CRESY 0.46
- SVRA 0.18
- MACD
- CRESY -0.05
- SVRA -0.02
- Stochastic Oscillator
- CRESY 35.21
- SVRA 52.80
About CRESY Cresud S.A.C.I.F. y A.
Cresud SACIF y A is engaged in agricultural business and urban properties and investment business. Under its agricultural business the company produces oilseed grains and cereals, sugar cane and meat. The Agricultural business of the company is further comprised of four reportable segments which are Agricultural production, Land transformation and Sales, Corporate and Other segments. The company participates in the real estate business in Argentina through its subsidiary IRSA. The real estate business is further comprised of five reportable segments, namely Shopping Malls, Offices, Sales and Developments, Hotels and others.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.